



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Review



Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review

Nicola Veronese^{a,*}, Mirko Petrovic^b, Athanase Benetos^c, Michael Denking^d, Adalsteinn Gudmundsson^e, Wilma Knol^f, Christine Marking^g, George Soulis^h, Stefania Maggiⁱ, Antonio Cherubini^j, on behalf of the special interest group in Systematic Reviews and Meta-analyses and the task force on Pharmaceutical strategy of the European Geriatric Medicine Society (EuGMS)

^a Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy

^b Section of Geriatrics, Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium

^c Department of Geriatrics and FHU CARTAGE-PROFILES, CHRU de Nancy and INSERM 1116, Université de Lorraine, Vandoeuvre-lès-Nancy, France

^d Institute for Geriatric Research at Agaplesion Bethesda Hospital Ulm, Ulm University and Geriatric Centre, Ulm, Germany

^e Landspítali University Hospital, Landspítali, Reykjavik, Iceland

^f Department of Geriatric Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

^g Memory Disorder Research Group, Department of Neurology, Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Denmark

^h Outpatient Geriatric Assessment Unit, Henry Dunant Hospital Center, Athens, Greece

ⁱ CNR-IN Aging Branch, Padua, Italy

^j Geriatria, Accettazione geriatrica e Centro di ricerca per l'invecchiamento, IRCCS INRCA, Ancona, Italy

ARTICLE INFO

Keywords:
COVID-19
Vaccination
Older adults

ABSTRACT

During the COVID-19 pandemic older subjects have been disproportionately affected by the disease. Vaccination is a fundamental intervention to prevent the negative consequences of COVID-19, but it is not known if the needs and vulnerabilities of older people are adequately addressed by their inclusion in randomized clinical trials (RCTs) evaluating the efficacy of vaccines for COVID-19. Given this background, we aimed to evaluate if current and ongoing phase II-III RCTs evaluating the efficacy of COVID-19 vaccines included a representative sample of older people. A systematic literature search in PubMed and Clinicaltrials.gov was performed until May 01st, 2021. Among 474 abstracts initially retrieved, 20 RCTs (ten already published, ten ongoing) were included. In the ten studies already published, the mean age of participants was 45.2 ± 11.9 years and only 9.83% of the participants were more than 65 years, 1.66% more than 75 years and less than 1% (0.55%) more than 85 years. In the ten ongoing RCTs, many of the studies aimed at including participants older than 18 years, with one study including participants between 18 and 84 years, and two between 21 and 100 years. In conclusion, our systematic review demonstrates that in published and ongoing phase II-III randomized clinical trials evaluating the efficacy of COVID-19 vaccines only a tiny fraction of the most vulnerable group of older people was included, although they clearly were the first population that had to be vaccinated.

1. Introduction

History will remember the year 2020 as the beginning of the most devastating pandemic after the Spanish flu, one century ago. Opposite to the influenza virus, the SARS-CoV-2 is a new virus for the human kind which contributed to its rapid spread and its ability to cause a pandemic which is still ongoing. The Coronavirus disease (COVID-19) most

strongly affects older adults: they are more likely to experience severe disease, to be hospitalized and account for the vast majority of COVID-19 related deaths (Onder et al., 2020).

A rapid review performed to assess the magnitude of the association between risk factors and severity of COVID-19 to inform the prioritization of vaccine administration in Canada concluded that older age seems the most important risk factor associated with higher probability

* Correspondence to: Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127 Palermo, Italy.
E-mail address: nicola.veronese@unipa.it (N. Veronese).




Fig. 1. PRISMA flow-chart.

of severe outcomes (Jentsch et al., 2021). Patients older than 60 years have an at least five times higher risk of hospitalization and mortality from COVID-19 in comparison with those younger than 45 years (Wingert et al., 2021).

Early in the pandemic, scientists began to evaluate potential treatments for the disease and to develop vaccines. After more than one year, while the search for a very effective drug is still ongoing, several vaccines have been developed and marketed, characterized by high efficacy and effectiveness in preventing COVID-19 disease (Koirala et al., 2020; Soiza et al., 2021). This remarkable achievement has been obtained within a time frame that was extremely reduced compared to usual time of a vaccine development, which typically takes 5–10 years (Mahase, 2020). In order to achieve such a result, the different phases of vaccine development have been performed in parallel, without compromising the accuracy of the studies (Agency, 2021). Therefore, several vaccines have been authorized, after a careful evaluation in order to assure that they fulfilled all the requirements of quality, safety and efficacy that are requested by drug regulatory agencies.

Since older subjects have the highest risk of developing severe disease and to die from COVID-19, they have been identified in several countries as the first group to be vaccinated (Cylus et al., 2021; Hasan et al., 2021). Furthermore, older subjects might have a blunted response to vaccination, due to immunosenescence (Crooke et al., 2019), as well

as to common occurrence of diseases and conditions inducing immunological impairment and to pharmacological therapies that reduce immune response (Ciabattini et al., 2020). A previous work published by Helfand et al. suggested that RCTs for COVID-19, registered at clinicaltrials.gov, were likely to exclude older adults (Helfand et al., 2020). Finally, several Phase III clinical trials investigating vaccine safety and efficacy have been published and many others are ongoing but it was reported that participants enrolled in these studies are limited by trial selection criteria, including age limitation (Kwok, 2021).

Given this background, the aim of this systematic review was to investigate whether published and ongoing phase II-III randomized clinical trials evaluating the efficacy of COVID-19 vaccines included a representative sample of older adults.

2. Materials and methods

2.1. Data sources and literature search strategy

Two investigators (NV and AC) conducted a systematic literature search PubMed and Clinicaltrials.gov without language restriction, from database inception to 01st May 2021. The search syntax is fully reported in Supplementary Table 1.

Table 1
Published Randomized controlled trials on the effect of SARS-CoV-2 Vaccination: characteristics and age distribution of participants.

Vaccine	Vaccine type	Phase	N	Health status	Age criteria included in the protocol	Mean age	SD age	Calculated upper 95% CI	Calculated 99% upper CI	% ≥ 65 years	% ≥ 75 years	% ≥ 85 years
Ad26. CoV	Viral vector	Phase 1–2	805	Healthy	18–88 years	52.6	7.1	53.09	53.25	50.00	7.00	0.25
Ad5	Viral vector	Phase 2	603	Healthy	18 Years and older	39.7	12.5	40.70	41.01	NA	NA	NA
BBIBP-CorV	Inactivated virus	Phase 2	448	Healthy	18–59 years	41.7	9.9	42.62	42.91	0.00	0.00	0.00
BNT162b2	mRNA	Phase 1–2	76	Healthy	18–55 years	35.4	NA	NA	NA	0.00	0.00	0.00
ChAdOx1 (AZS1222)	Viral vector	Phase 2–3	11,636	Healthy. at high risk of exposure	18 Years and older	NA	NA	NA	NA	3.81	NA	NA
CoronaVac	Inactivated virus	Phase 1–2	673	Healthy	18–55 years	42.6	9.4	43.31	43.53	0.00	0.00	0.00
Gam-COVID-Vac (Sputnik V)	Viral vector	Phase 3	19,866	Healthy	18 Years and older	45.3	12	45.47	45.52	> 60 years: 10.8%	NA	NA
mRNA-1273	mRNA	Phase 3	30,351	No inclusion criteria pre-specified	18–95 years	51.4	NA	NA	NA	24.80	4.60	0.30
NVX-CoV2373	Protein subunit	Phase 2	131	Healthy	18–59 years	30.8	10.2	32.55	33.10	0.00	0.00	0.00
WIV04	Inactivated virus	Phase 2	224	Healthy	18–59 years	43.5	9.1	44.69	45.07	0.00	0.00	0.00
Total			64,813			45.2	11.9	45.29	45.32	9.83	1.66	0.55

2.2. Study selection

Inclusion criteria for this systematic review were: (i) being a RCT; (ii) double-blind design; (iii) participants treated with a SARS-CoV-2 vaccine; (iv) one group taking placebo; (v) being in a clinical phase, i.e., at least in phase II of an RCT. We have therefore excluded: (i) phase I RCTs; (ii) no original data, such as reviews and commentaries.

2.3. Data extraction

Two investigators (NV and AC) extracted key data from the included articles in a standardized Excel sheet. For each article, we extracted data about authors, year of publication, name and type of the vaccine, phase of the RCT, age criteria included in the protocol, health status of the participants included, reported mean age with standard deviation and overall sample size. When some information regarding age was missing, first and/or corresponding authors of the original article were contacted at least two times in one month to obtain unpublished data. Only one author of the published articles responded answered to our request.

2.4. Outcomes

The main outcome of our work was to evaluate the inclusion of older adults in RCTs of SARS-CoV-2 vaccines in both published and ongoing RCTs. To this purpose, we have extracted the data regarding mean age and the age criteria used in the protocol/published works, asking for other details if needed. Moreover, we calculated with standardized formulas the 95% and the 99% confidence intervals reporting the upper limit for the aims of our work. Finally, we have also reported data regarding the percentage of people older than 65, 75, and 85 years respectively, i.e. commonly used age cut-offs in geriatric medicine (Kowal and Dowd, 2001).

3. Results

3.1. Literature search

Fig. 1 shows the results of the literature search. Overall, 474 abstracts were retrieved, and 27 full texts were screened. Among them, 20




Fig. 2. Graphical representation of age distribution in the randomized controlled trials included. The Blue area represents people between 45.2 years (calculated mean) and 65 years; the yellow area participants between 65 and 75 years; the orange area those between 75 and 85 years; the white area participants with more than 85 years. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

studies (ten already published, ten ongoing) were included for the current analysis.

3.2. Published works

Table 1 summarizes the data regarding all ten already published RCTs on SARS-CoV-2 vaccines (Baden et al., 2021; Keech et al., 2020; Logunov et al., 2021; Mulligan et al., 2020; Sadoff et al., 2021; Voysey et al., 2021; Xia et al., 2020, 2021; Zhang et al., 2021; Zhu et al., 2020). Different vaccine designs were tested. Overall, four studies used viral vector, three inactivated virus, two mRNA and one study protein sub-unit vaccines. Four RCTs were of phase II, three in phase I-II, two in

Table 2
Characteristics of ongoing phase 3–4 randomized controlled trials on the effect of SARS-CoV-2 Vaccination.

NCT Number	Title	Vaccine type	Phase	Age
NCT04439045	Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity	VPM1002	Phase 3	18 Years and older
NCT04510207	A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above	Inactivated SARS-CoV-2 Vaccine (Vero cell)	Phase 3	18 Years and older
NCT04583995	A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom	SARS-CoV-2 rS/Matrix M1-Adjuvant	Phase 3	18 Years to 84 Years
NCT04612972	Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru	Inactivated SARS CoV 2 vaccine (Vero cell)	Phase 3	18 Years to 60 Years
NCT04640233	Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- Δ CoV-2) Infection	Gam-COVID-Vac	Phase 2–3	18 Years and older
NCT04646590	A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19	Recombinant new coronavirus vaccine (CHO cell) group	Phase 3	18 Years and older
NCT04649515	Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans	TY027	Phase 3	21 Years to 100 Years
NCT04651790	Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults	SARS-CoV-2 inactivated vaccine	Phase 3	18 Years and older
NCT04659239	The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19	Inactivated SARS-CoV-2 Vaccine (Vero cell)	Phase 3	18 Years and older
NCT04747821	An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine	Adsorbed COVID-19 (Inactivated) Vaccine	Phase 4	18 Years and older

phase III and one in phase II-III. Overall, the majority of the studies ($n = 8$) included only healthy individuals.

Regarding the age criteria reported in the protocols, in the full-texts and asked to the authors, as shown in Table 1, three studies included participants between 18 and 59 years, three studies people aged > 18 years, two studies people aged between 18 and 55 years, and the other two studies had an upper age limit at 88 and 95 years, respectively.

The mean age reported in the full-texts, in the regulatory documents or provided by the corresponding authors was 45.2 ± 11.9 years that

leads to a 95% higher confidence of interval of 45.29 years and 99% of 45.32 years. Given these figures, only 9.83% of the subjects included were older than 65 years, 1.66% older than 75 years and less than 1% (0.55%) older than 85 years. These findings are reported in a graphical way in Fig. 2.

3.3. Ongoing works

Table 2 shows the 10 ongoing RCTs on SARS-CoV-2 vaccines. Overall, 8/10 studies were phase III, one in phase IV and a final one in phase II-III. The majority of the studies included participants older than 18 years, one study between 18 and 84 years, and another two between 21 and 100 years without more information about the age strata to date.

4. Discussion

In this systematic review including twenty studies, out of which ten are still ongoing, we found that the presence of older adults was extremely limited. In ten already published studies less than 10% of the participants included were older than 65 years and, only less than 1% of them were older than 85 years. In ongoing RCTs, the majority declared to include subjects older than 18 years without an upper age limit but also without prespecified strata.

Overall, our work confirms the long-standing issue of underrepresentation of older adults in RCTs (Cherubini et al., 2010; Crome et al., 2014). While COVID-19 disease can affect subjects of any age, the majority of patients who suffer from severe disease including long-lasting syndromes (such as “Long COVID”) and experience high case fatality are older adults. (Onder et al., 2020) Moreover, several consequences of long COVID syndrome in older people are still not known (Reid et al., 2021). Therefore, in almost every country across the world, the first population that was vaccinated against COVID-19 were older adults and, in particular, the most vulnerable and frail, such as nursing home residents (Dooling et al., 2020). Although observational studies confirm effectiveness of vaccine also in nursing home residents with respect to symptomatic infection of COVID-19 disease (McEllistrem et al., 2021) and mortality (Wyller et al., 2021), no systematic reviews and controlled trials with a substantial proportion of older participants is available or in sight. To the contrary, mean age of included participants in Phase II/III RCTs was about 45 years. The main causes of the underrepresentation of older adults in clinical trials on COVID-19 vaccines are the selection criteria of the trials (Zhu et al., 2020). First of all, many of them had an upper age limit, that prevented the participation of older adults (Zhu et al., 2020). Even when an upper age limit was not present (Keech et al., 2020; Voysey et al., 2021; Xia et al., 2020; Zhang et al., 2021), the presence of other indirect criteria, such as the exclusion of specific diseases, e.g. chronic diseases or drugs, such as anticoagulants (Voysey et al., 2021; Zhu et al., 2020), disproportionately disadvantage older adults (Cherubini et al., 2011). While the exclusion of vulnerable subjects might be justifiable in the context of phase I or even phase 2 clinical trials, many published trials were phase 3 trials (Baden et al., 2021; Logunov et al., 2021; Voysey et al., 2021), which are performed in order to demonstrate efficacy and safety of a treatment in order to request authorization by regulatory agencies.

This evidence is a further proof of the concept that medications and vaccines commonly used in older adults have not been adequately evaluated in this population. The underrepresentation of older adults in RCTs can have important consequences as it prevents an adequate knowledge of the efficacy and safety of COVID-19 vaccines in a patient group with significant pharmacokinetic and dynamic changes, multimorbidity and polypharmacy, that all can affect efficacy and safety of drugs (Mangoni et al., 2015). This could lead to a higher susceptibility to develop adverse drug events (Davies and O'mahony, 2015; Zazzara et al., 2021), as for example in the case of spironolactone for heart failure which was clearly beneficial in younger (Pitt et al., 1999), but increased mortality in older adults (Juurlink et al., 2004; Pitt et al.,

1999). It is also well known that older subjects tend to have a blunted response to vaccines, due to immunosenescence (Crooke et al., 2019), and this might also apply to vaccines used to prevent COVID-19 disease.

Another important aspect to discuss is that also ongoing RCTs that will lead to the approval of new anti-COVID-19 vaccines in the next future will likely not include a relevant percentage of older adults nor will they include any measure of physical frailty or other functional parameters needed. This is, again, in contrast with the strict indications of the most important international organization in the world, such as the World Health Organization (Girard et al., 2011) and the European Medicine Agency that strongly encourage the inclusion of older adults in the RCTs and propose also using frailty measures to better characterize this heterogeneous population (Agency, 2018; Cerreta et al., 2012).

Our findings have several implications. First of all, the underrepresentation of older people implies that the real efficacy and safety of vaccines in this large group, the one most severely affected by COVID-19, are not well characterized. Consequently, the use of vaccines in older people does not fulfill the criteria of evidence based medicine, which require that solid scientific evidence should be available to support the implementation of a new intervention, e.g. vaccination. Therefore, COVID-19 vaccines have been used in older subjects without a proper knowledge of their efficacy and safety in this heterogeneous population. This means also, from an ethical point of view, that older people are discriminated, being denied the right to receive evidence based treatment, as advocated by the Charter elaborated within the PREDICT study (Crome et al., 2014). Moreover, the lack of adequate scientific data in older adults, might undermine the public trust concerning using the vaccines in frail older adults. Finally, these results represent an important warning for researchers who are planning or conducting studies to evaluate preventive or therapeutic interventions against COVID-19 disease to include an adequate number of older subjects in order to assure the generalizability of their findings.

The findings of our review should be interpreted within certain limitations. First, several studies did not include sufficient information regarding age: even if we tried to reach the corresponding authors of the published works, only one answered to our request to provide the additional information. Second, we are not able to synthesize in case of inclusion of older people if they are representative of older population (e.g., adequate presence of people having comorbidities or other geriatric conditions of clinical importance, such as frailty and dementia).

In conclusion, our systematic review found that in published and ongoing phase II-III randomized clinical trials evaluating the efficacy of COVID-19 vaccines, a tiny fraction of older adults was included, even if older people were the most affected by COVID-19 disease and therefore the first population to be vaccinated. This finding further underlines the fact that we need an important change in attitude and policy actions to promote the inclusion in RCTs of all relevant groups of people in which medications and vaccines are used, including older adults.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.arr.2021.101455](https://doi.org/10.1016/j.arr.2021.101455).

References

- Agency, E.M., 2018. Physical frailty: instruments for baseline characterisation of older populations in clinical trials.
- Agency, E.M., 2021. COVID-19 vaccines: development, evaluation, approval and monitoring.
- Baden, L.R., Sahly, El, Essink, H.M., Kotloff, B., Frey, K., Novak, S., Diemert, R., Spector, D., Roupael, S.A., Creech, N., McGettigan, C.B., Khetan, J., Segall, S., Solis, N., Brosz, J., Fierro, A., Schwartz, C., Neuzil, H., Corey, K., Gilbert, L., Janes, P., Follmann, H., Marovich, D., Masciola, M., Polakowski, J., Ledgerwood, L., Graham, J., Bennett, B.S., Pajon, H., Knightly, R., Leav, C., Deng, B., Zhou, W., Han, H., Ivarsson, S., Miller, M., Zaks, J., Group, C.S. T., 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med.* 384, 403–416.
- Cerreta, F., Eichler, H.-G., Rasi, G., 2012. Drug policy for an aging population – the European Medicines Agency’s geriatric medicines strategy. *N. Engl. J. Med.* 367, 1972–1974.
- Cherubini, A., Oristrell, J., Pla, X., Ruggiero, C., Ferretti, R., Diestre, G., Clarfield, A.M., Crome, P., Hertogh, C., Lesauskaite, V., 2011. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. *Arch. Intern. Med.* 171, 550–556.
- Cherubini, A., Signore, S.D., Ouslander, J., Semla, T., Michel, J.P., 2010. Fighting against age discrimination in clinical trials. *J. Am. Geriatr. Soc.* 58, 1791–1796.
- Ciabattini, A., Garagnani, P., Santoro, F., Rappuoli, R., Franceschi, C., Medagliani, D., 2020. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population. *Semin. Immunopathol.* 1–16 (Springer).
- Crome, P., Cherubini, A., Oristrell, J., 2014. The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. *Expert Rev. Clin. Pharmacol.* 7, 457–468.
- Crooke, S.N., Ovsyannikova, I.G., Poland, G.A., Kennedy, R.B., 2019. Immunosenescence and human vaccine immune responses. *Immun. Ageing* 16, 1–16.
- Cylus, J., Panteli, D., van Ginneken, E., 2021. Who should be vaccinated first? Comparing vaccine prioritization strategies in Israel and European countries using the Covid-19 Health System Response Monitor. *Isr. J. Health Policy Res.* 10, 1–3.
- Davies, E., O’mahony, M., 2015. Adverse drug reactions in special populations – the elderly. *Br. J. Clin. Pharmacol.* 80, 796–807.
- Dooling, K., McClung, N., Chamberland, M., Marin, M., Wallace, M., Bell, B.P., Lee, G.M., Talbot, H.K., Romero, J.R., Oliver, S.E., 2020. The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine – United States, 2020. *Morb. Mortal. Wkly. Rep.* 69, 1857–1859.
- Girard, M.P., Katz, J.M., Pervikov, Y., Hombach, J., Tam, J.S., 2011. Report of the 7th meeting on evaluation of pandemic influenza vaccines in clinical trials, World Health Organization, Vaccine 29, Geneva, 17–18 February, 2011, pp. 7579–7586.
- Hasan, T., Beardsley, J., Marais, B.J., Nguyen, T.A., Fox, G.J., 2021. The implementation of mass-vaccination against SARS-CoV-2: a systematic review of existing strategies and guidelines. *Vaccines* 9, 326.
- Helfand, B.K., Webb, M., Gartaganis, S.L., Fuller, L., Kwon, C.-S., Inouye, S.K., 2020. The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019—missing the target. *JAMA Intern. Med.* 180, 1546–1549.
- Jentsch, P.C., Anand, M., Bauch, C.T., 2021. Prioritizing COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. *Lancet Infect. Dis.* 21, 1097–1106.
- Juurink, D.N., Mamdani, M.M., Lee, D.S., Kopp, A., Austin, P.C., Laupacis, A., Redelmeier, D.A., 2004. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. *N. Engl. J. Med.* 351, 543–551.
- Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J.S., Zhu, M., Cloney-Clark, S., Zhou, H., Smith, G., Patel, N., Frieman, M.B., Haupt, R.E., Logue, J., McGrath, M., Weston, S., Piedra, P.A., Desai, C., Callahan, K., Lewis, M., Price-Abbott, P., Formica, N., Shinde, V., Fries, L., Lickliter, J.D., Griffin, P., Wilkinson, B., Glenn, G.M., 2020. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *N. Engl. J. Med.* 383, 2320–2332.
- Koirala, A., Joo, Y.J., Khatami, A., Chiu, C., Britton, P.N., 2020. Vaccines for COVID-19: the current state of play. *Paediatr. Respir. Rev.* 35, 43–49.
- Kowal, P., Dowd, J.E., 2001. Definition of an Older Person. Proposed Working Definition of an Older Person in Africa for the MDS Project. World Health Organization, Geneva doi 10, 5188.9286.
- Kwok, H.F., 2021. Review of Covid-19 vaccine clinical trials – a puzzle with missing pieces. *Int. J. Biol. Sci.* 17, 1461–1468.
- Logunov, D.Y., Dolzhikova, I.V., Shcheblyakova, D.V., Tukhvatulin, A.I., Zubkova, O.V., Dzharullaeva, A.S., Kovyrshina, A.V., Lubenets, N.L., Grousova, D.M., Erokhova, A. S., Botikov, A.G., Izhayeva, F.M., Popova, O., Ozharovskaya, T.A., Esmagambetov, I. B., Favorskaya, I.A., Zrelkin, D.I., Voronina, D.V., Shcherbinin, D.N., Semikhin, A.S., Simakova, Y.V., Tokarskaya, E.A., Egorova, D.A., Shmarov, M.M., Nikitenko, N.A., Gushchin, V.A., Smolyarchuk, E.A., Zryzyanov, S.K., Borisevich, S.V., Naroditsky, B. S., Gintsburg, A.L., 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 397, 671–681.
- Mahase, E., 2020. Covid-19: what do we know so far about a vaccine? *BMJ* m1679.
- Mangoni, A.A., Jansen, P.A., Jackson, S.H., 2015. Pharmacokinetic and pharmacodynamic studies in older adults. *Clin. Trials Older Adults* 79–94.
- McEllistrem, M.C., Clancy, C.J., Buehrle, D.J., Lucas, A., Decker, B.K., 2021. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19. *Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am.*
- Mulligan, M.J., Lyke, K.E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K.A., 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 586, 589–593.
- Onder, G., Rezza, G., Brusaferro, S., 2020. Characteristics of patients dying in relation to COVID-19 in Italy *JAMA* Published online March 23.
- Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J., Wittes, J., 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N. Engl. J. Med.* 341, 709–717.
- Reid, H., Miller, W.C., Esfandiari, E., Mohammadi, S., Rash, I., Tao, G., Simpson, E., Leong, K., Matharu, P., Sakakibara, B., Schmidt, J., Jarus, T., Forwell, S., Borisoff, J., Backman, C., Alic, A., Brooks, E., Chan, J., Flockhart, E., Irish, J., Tsukura, C., Dispirito, N., Mortenson, B., 2021. The impact of COVID-19 related restrictions on social and daily activities of parents, people with disabilities and older adults: protocol for a longitudinal, mixed-methods study. *JMIR Res. Protoc.* 10, 28337.

- Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A.M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K.E., De Rosa, S.C., Cohen, K.W., McElrath, M.J., Cormier, E., Scheper, G., Barouch, D.H., Hendriks, J., Struyf, F., Douougih, M., Van Hoof, J., Schuitemaker, H., 2021. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. *N. Engl. J. Med.* 384, 1824–1835.
- Soiza, R.L., Scicluna, C., Thomson, E.C., 2021. Efficacy and safety of COVID-19 vaccines in older people. *Age Ageing* 50, 279–283.
- Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus, B., Baillie, V.L., Barnabas, S.L., Borat, Q.E., 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 397, 99–111.
- Wingert, A., Pillay, J., Gates, M., Guitard, S., Rahman, S., Beck, A., Vandermeer, B., Hartling, L., 2021. Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada. *BMJ Open* 11, 044684.
- Wyller, T.B., Kittang, B.R., Ranhoff, A.H., Harg, P., Myrstad, M., 2021. Nursing home deaths after COVID-19 vaccination. *Tidsskr. Den. Nor. Laege.: Tidsskr. Prakt. Med., Ny. raekke* 141.
- Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., Yang, Y., Chen, W., Gao, X., You, W., Wang, X., Wang, Z., Shi, Z., Wang, Y., Yang, X., Zhang, L., Huang, L., Wang, Q., Lu, J., Yang, Y., Guo, J., Zhou, W., Wan, X., Wu, C., Wang, W., Huang, S., Du, J., Meng, Z., Pan, A., Yuan, Z., Shen, S., Guo, W., Yang, X., 2020. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. *JAMA* 324, 951–960.
- Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G.F., Tan, W., Wu, G., Xu, M., Lou, Z., Huang, W., Xu, W., Huang, B., Wang, H., Wang, W., Zhang, W., Li, N., Xie, Z., Ding, L., You, W., Zhao, Y., Yang, X., Liu, Y., Wang, Q., Huang, L., Yang, Y., Xu, G., Luo, B., Wang, W., Liu, P., Guo, W., Yang, X., 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect. Dis.* 21, 39–51.
- Zazzara, M.B., Palmer, K., Vetrano, D.L., Carfi, A., Graziano, O., 2021. Adverse drug reactions in older adults: a narrative review of the literature. *Eur. Geriatr. Med.* 1–11.
- Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., Zhu, F., 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect. Dis.* 21, 181–192.
- Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., Zhang, J., Qian, X.-A., Li, Q., Pan, H.-X., Jiang, H.-D., Deng, P., Gou, J.-B., Wang, X.-W., Wang, X.-H., Chen, W., 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 396, 479–488.